CompletedNCT01009047
Extended-release paliperidone or aripiprazole for teen schizophrenia
About this title
Read the official source — NCT01009047Medication studyAges 12–17Multiple countries
Understand this study
Who was this study for?
Listed age limits: 12 years to 17 years.
- Listed locations
- Dothan and 40 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateDecember 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 228
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, India, Romania, ...
- Age range
- From 12 Years to 17 Years
- Official registry ID
- NCT01009047
- Official title
Show the full official title
A Randomized, Multicenter, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Symptoms of Schizophrenia in Adolescent Subjects, 12 to 17 Years of Age
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedDothan, United States · Santa Ana, United States · Atlanta, United States
39 more locations
- Smyrna, United States
- Lake Charles, United States
- Shreveport, United States
- Jaipur, India
- Kanpur Uttarpradeh, India
- Lucknow Gpo, India
- Mangalore, India
- Varanasi, India
- Bucharest, Romania
- Chelyabinsk, Russia
- Ekaterinburg Na, Russia
- Krasnodar, Russia
- Moscow, Russia
- Moscow Russia, Russia
- Nizhny Novgorod, Russia
- Novosibirsk, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Saratov, Russia
- Smolensk Region N/A, Russia
- Tomsk Na, Russia
- Yaroslavl, Russia
- Bratislava, Slovakia
- Badajoz, Spain
- Esplugues de Llobregat, Spain
- Madrid, Spain
- Paterna, Spain
- Sabadell, Spain
- Seville, Spain
- Valladolid, Spain
- Donetsk, Ukraine
- Hlevakha, Ukraine
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kiev, Ukraine
- Poltava, Ukraine
- Simferopol, Ukraine
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone extended release (ER) and Aripiprazole.
Who was this study for?
Listed age limits: 12 years to 17 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia